Related Party Transactions - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
|
| Related Party Transaction [Line Items] | |||||
| Research and development | $ 18,048 | $ 17,185 | $ 38,919 | $ 30,221 | |
| Sale of stock issue price per share | $ 30.75 | $ 30.75 | |||
| License Agreement [Member] | |||||
| Related Party Transaction [Line Items] | |||||
| Amount Due to Related Party | $ 0 | $ 0 | $ 0 | ||
| Research and development | 100 | 100 | 100 | 100 | |
| Member of the Scientific Advisory Board [Member] | Advisory Services Agreement [Member] | |||||
| Related Party Transaction [Line Items] | |||||
| Professional fees | 100 | $ 100 | 100 | $ 100 | |
| Amount Due to Related Party | $ 0 | $ 0 | $ 0 | ||
| X | ||||||||||
- Definition Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|